论文部分内容阅读
磷酸二酯酶(Phosphodiesterase,PDE)抑制剂临床药物有选择性和非选择性两类。是以舒张平滑肌和心肌正性肌力作用广泛应用于临床解痉、止喘、扩冠、强心、利尿。选择性PDE抑制剂应用起步较晚。由于其对组织的选择性,而副作用少,个体特性突出。非选择性PDE抑制剂应用较早。其主要代表药物茶硷30年代就用于临床治疗哮喘,并以其舒张支气管的肯定疗效而成为哮喘治疗一线药物。随着对哮喘本质的认识发展和治疗观念的转变,及各种介质抑制剂、受体拮抗剂、炎症反应抑制剂的研究进展,使茶硷的治疗哮喘地位受到挑战。
Phosphodiesterase (PDE) inhibitor clinical drugs are selective and non-selective two categories. Is based on the relaxation of smooth muscle and cardiac muscle positive role widely used in clinical spasticity, Zhichuan, crown expansion, cardiac, diuretic. Selective PDE inhibitors started late. Due to its selectivity to the organization, with fewer side effects, individual characteristics stand out. Non-selective PDE inhibitors are used earlier. Its main representative drug theophylline 30 years for the clinical treatment of asthma, bronchial and its diastolic function as the first-line treatment of asthma drugs. With the understanding of the nature of the development of asthma and the treatment of the concept of change, and a variety of media inhibitors, receptor antagonists, inhibitors of inflammatory response progress, so that the theophylline treatment of asthma status challenged.